Modality
Small Molecule
MOA
CAR-T CD19
Target
CD47
Pathway
Incretin
PsA
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
Jul 2020
→ Jan 2028
Phase 1Current
NCT06269416
2,497 pts·PsA
2021-01→2027-08·Active
NCT04440071
1,707 pts·PsA
2020-07→2028-01·Not yet recruiting
4,204 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-281.4y awayPh2 Data· PsA
2028-01-061.8y awayPh2 Data· PsA
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Not yet…
P1/2
Active
Catalysts
Ph2 Data
2027-08-28 · 1.4y away
PsA
Ph2 Data
2028-01-06 · 1.8y away
PsA
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06269416 | Phase 1/2 | PsA | Active | 2497 | PANSS |
| NCT04440071 | Phase 1/2 | PsA | Not yet recr... | 1707 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |